🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Austria
Clinical trial register · Austria

Studies with an Austrian investigative site

Every study on the ClinicalTrials.gov registry that lists a site in Austria and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 1573 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:45 UTC
1573
Studies in scope
all four open statuses
850
Recruiting now
open to new participants
339
Lead sponsors
across recruiting studies
Top sites
Vienna 1005 Graz 506 Linz 438 Innsbruck 398 Salzburg 291
Narrow the register
Recruitment status
Phase
Lead sponsor
Medical University of Vienna148 Medical University of Graz86 AstraZeneca54 Medical University Innsbruck42 Novartis Pharmaceuticals41
Site location
Vienna1005 Graz506 Linz438 Innsbruck398 Salzburg291
All 97 locations
Target enrolment
to

Trials in this register

1573 of 1573 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Austria
Start
Recruiting
Validation of Continuous Transcutaneous Carbon Dioxide Monitoring in VA-ECMO Patients
NCT04445909Carbon Dioxide
Medical University of Vienna
Observational
30
Vienna
2019-11-18
Active, closed
Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia
NCT04232241Acute Myeloid Leukemia in Remission, Acute Lymphoblastic Leukemia in Remission, Myelodysplastic Syndromes
Universitätsklinikum Hamburg-Eppendorf
Phase 2
167
Graz, Innsbruck, Vienna
2019-11-14
Recruiting
APrevent-VOIS-Implant-002 - a Two-Part, Open-Label, Non-Randomized Multicenter Study
NCT05119842Paralysis, Unilateral, Vocal Cord
APrevent Biotech GmbH
Not applicable
30
Vienna
2019-11-13
Recruiting
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)
NCT04221035High-Risk Neuroblastoma, Patient With Insufficient Response Chemoimmunotherapy
DrugsVindesine·Busulfan·Dacarbazine·Ifosfamide
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3
800
Graz, Innsbruck, Linz, Salzburg, Vienna
2019-11-05
Active, closed
Safety and Efficacy of Silk Vista and Silk Vista Baby Flow Diverter for Intracranial Aneurysm Treatment
NCT04034810Intracranial Aneurysm, Flow Diverter
Balt Extrusion
Observational
234
Salzburg
2019-11-04
Active, closed
An All-Comers Observational Study of the MicroStent™ Peripheral Vascular Stent System in Subjects With Peripheral Arterial Disease
NCT04110327Peripheral Arterial Disease, Critical Lower Limb Ischemia
Micro Medical Solution, Inc.
Observational
300
Graz
2019-10-31
By invitation
A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
NCT04138927Warm Antibody Autoimmune Hemolytic Anemia
Rigel Pharmaceuticals
Phase 3
90
Vienna
2019-10-30
Active, closed
Deciphering AMD by Deep Phenotyping and Machine Learning- Prospective Study - PINNACLE
NCT04269304Age-related Macular Degeneration
University of Southampton
Observational
429
Vienna
2019-10-28
Active, closed
Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma
NCT04099251Melanoma
DrugsOpdivo·Nivolumab
Bristol-Myers Squibb
Phase 3
790
Graz, Innsbruck, Salzburg, Vienna
2019-10-28
Recruiting
Boston Scientific Registry of Deep Brain Stimulation for Treatment of Essential Tremor (ET)
NCT04032470Essential Tremor
Boston Scientific Corporation
Observational
500
Innsbruck
2019-10-23
Active, closed
Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia With Inhibitors
NCT04083781Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
DrugConcizumab
Novo Nordisk A/S
Phase 3
134
Vienna
2019-10-21
Recruiting
Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment
NCT04045691Melanoma Stage IV, Melanoma Stage III
DrugsBinimetinib·Encorafenib
Pierre Fabre Pharma GmbH
Observational
750
Graz, Innsbruck, Klagenfurt, Linz, Salzburg, Vienna, Wiener Neustadt
2019-10-17
Recruiting
Phenotypes, Biomarkers and Pathophysiology in Hereditary Spastic Paraplegias and Related Disorders
NCT03981276Hereditary Spastic Paraplegia
Dr. Rebecca Schule
Observational
2,000
Innsbruck
2019-10-14
Active, closed
SyncAV Post-Market Trial
NCT04100148Congestive Heart Failure
Abbott Medical Devices
Not applicable
1,686
Graz
2019-10-03
Active, closed
A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer
NCT03975647HER2-positive Breast Cancer
DrugsTucatinib·Trastuzumab emtansine
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
466
Innsbruck, Vienna
2019-10-02
Active, closed
Comprehensive Long-term Follow up of Adults With Arterial Switch Operation
NCT04335448Transposition of Great Vessels
University of Zurich
Observational
540
Vienna
2019-10-01
By invitation
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)
NCT04093570Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes
DrugDecitabine
Taiho Oncology, Inc.
Phase 2
332
Vienna
2019-09-30
Active, closed
Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations
NCT04006210Parkinson's Disease
NeuroDerm Ltd.
Phase 3
381
Innsbruck
2019-09-30
Recruiting
A Post-Authorisation Safety Study Patient Registry of Patients With Neuroblastoma Being Treated With Dinutuximab Beta
NCT04253015Neuroblastoma
RECORDATI GROUP
Observational
125
Vienna
2019-09-30
Active, closed
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
NCT04033445Ulcerative Colitis
DrugGuselkumab
Janssen Research & Development, LLC
Phase 2/3
1,064
Salzburg
2019-09-26
By invitation
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
NCT03683186PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension
United Therapeutics
Phase 3
1,000
Innsbruck, Linz, Vienna
2019-09-23
Active, closed
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
NCT03844048Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Non-Hodgkin's Lymphoma
DrugsVenclexta·Venetoclax
AbbVie
Phase 3
165
Graz
2019-09-06
Active, closed
An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis
NCT03950232Ulcerative Colitis
DrugEtrasimod
Pfizer
Phase 3
896
Vienna
2019-09-05
Active, closed
Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics
NCT03897127Acute Myeloid Leukemia
DrugsLiposome-encapsulated Daunorubicin-Cytarabine·Daunorubicin·Cytarabine
University of Ulm
Phase 3
882
Graz, Innsbruck, Linz, Rankweil, Salzburg, Vienna
2019-09-04
Active, closed
Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer
NCT03820830Breast Cancer Recurrent
DrugPalbociclib
ETOP IBCSG Partners Foundation
Phase 3
405
Graz, Innsbruck, Salzburg, Vienna
2019-08-27
Active, closed
MiCLASP Post Market Clinical Follow-Up (PMCF) Study
NCT04430075Mitral Regurgitation, Mitral Insufficiency
Edwards Lifesciences
Observational
1,000
Vienna
2019-08-23
Recruiting
International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma
NCT04043494Lymphoblastic Lymphoma, Childhood
DrugsThioguanine·Vindesine·PEG asparaginase·Mercaptopurine
University Hospital Muenster
Phase 3
683
Graz, Innsbruck, Linz, Salzburg, Vienna
2019-08-23
Active, closed
A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation
NCT04002297Mantle Cell Lymphoma; Non-Hodgkin Lymphoma
DrugsBendamustine·Zanubrutinib·Rituximab
BeOne Medicines
Phase 3
510
Linz, Salzburg, Vienna
2019-08-20
Recruiting
Pan Tumor Rollover Study
NCT03899155Cancer
DrugsRucaparib·Sunitinib·Relatlimab·Trametinib
Bristol-Myers Squibb
Phase 2
1,500
Graz, Linz, Vienna, Wels
2019-08-09
Active, closed
A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)
NCT04008030Metastatic Colorectal Cancer
DrugsLeucovorin·Fluorouracil·Ipilimumab·Cetuximab
Bristol-Myers Squibb
Phase 3
839
Graz, Linz, Salzburg, Vienna, Wiener Neustadt
2019-08-05
Active, closed
Cell Therapy for Immunomodulation in Kidney Transplantation
NCT03867617Kidney Transplantation
DrugTocilizumab
Thomas Wekerle
Phase 1/2
12
Vienna
2019-08-01
Active, closed
A Research Study in Children Born Small and Who Stayed Small. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day
NCT03878446Short Stature Children Born Small for Gestational Age (SGA)
DrugsNorditropin·Somapacitan
Novo Nordisk A/S
Phase 2
62
Linz, Graz, Salzburg, Sankt Pölten, Vöcklabruck
2019-07-04
Active, closed
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
NCT03960840Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia
DrugIbrutinib
Novartis Pharmaceuticals
Phase 1/2
217
Vienna
2019-06-26
Active, closed
Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
NCT03937219Renal Cell Carcinoma
DrugsCabozantinib·Ipilimumab·Nivolumab
Exelixis
Phase 3
855
Wiener Neustadt, Linz, Salzburg, Vienna
2019-06-25
Recruiting
E²-RADIatE: EORTC-ESTRO RADiotherapy InfrAstrucTure for Europe
NCT03818503Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Observational
2,000
Graz, Linz, Vienna
2019-06-24
Active, closed
A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer
NCT03873402Renal Cell Carcinoma
DrugsIpilimumab·Nivolumab
Bristol-Myers Squibb
Phase 3
437
Graz, Vienna, Wels
2019-06-21
Active, closed
Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD)
NCT03992417Dermatitis Atopic
DrugDupilumab
Sanofi
Observational
955
Graz, Linz, Maria Enzersdorf, Vienna
2019-06-11
Active, closed
Evaluation of the Safety and Efficacy of TLD in Patients with COPD
NCT03639051COPD
Nuvaira, Inc.
Not applicable
464
Vienna
2019-05-23
Recruiting
Custodiol-N Solution Compared With Custodiol Solution in Organ Transplantation (Kidney, Liver and Pancreas)
NCT03627013Kidney Failure, Liver Failure, Chronic, Kidney-Pancreas Failure
DrugCustodiol-N
Dr. F. Köhler Chemie GmbH
Phase 3
362
Graz, Innsbruck, Linz, Vienna
2019-05-23
Active, closed
A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)
NCT03930953Lymphoma, Non-Hodgkin
DrugsValemetostat·Tafasitamab·Golcadomide·Obinutuzumab
Celgene
Phase 1/2
438
Salzburg, Sankt Pölten, Vienna
2019-05-20
Recruiting
Predominant Sensitizations to Single Bee Venom Allergens as a Risk Factor for Therapy Failure
NCT04259359Bee Venom Allergy
Medical University of Graz
Observational
266
Graz
2019-05-02
Active, closed
Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment
NCT03847428Hepatocellular Carcinoma
DrugsDurvalumab·Bevacizumab
AstraZeneca
Phase 3
908
Innsbruck, Linz, Sankt Pölten
2019-04-29
Active, closed
Inspiris Resilia Durability Registry
NCT03666741Aortic Valve Stenosis
Institut für Pharmakologie und Präventive Medizin
Observational
400
Sankt Pölten, Vienna
2019-04-26
Recruiting
A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis
NCT03773965Juvenile Idiopathic Arthritis
DrugBaricitinib
Eli Lilly and Company
Phase 3
190
Bregenz
2019-04-05
By invitation
A Study Following Males With Haemophilia B on Prophylaxis With Refixia/REBINYN
NCT03745924Haemophilia B
DrugNonacog beta pegol
Novo Nordisk A/S
Observational
60
Vienna
2019-04-01
Active, closed
Automatic PredICtion of Edema After Stroke
NCT04057690Stroke, Acute, Brain Edema
University Hospital Tuebingen
Observational
1,687
Vienna
2019-04-01
Active, closed
A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis
NCT03900429NASH - Nonalcoholic Steatohepatitis
DrugResmetirom
Madrigal Pharmaceuticals, Inc.
Phase 3
1,759
Klagenfurt, Vienna, Linz, Salzburg, Sankt Pölten, Wels
2019-03-28
Active, closed
Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy.
NCT03869892Metastatic Colorectal Cancer
DrugsTrifluridine/Tipiracil·Capecitabine
Institut de Recherches Internationales Servier
Phase 3
856
Graz, Innsbruck, Linz, Salzburg, Sankt Pölten, Vienna
2019-03-21
Active, closed
Acupuncture in Pediatrics and Adolescents With Chronic Inflammatory Bowel Diseases
NCT04488198Morbus Crohn, Colitis, Ulcerative
Medical University of Vienna
Not applicable
60
Vienna
2019-03-01
Active, closed
A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy
NCT03839771Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2
DrugsEnasidenib·Ivosidenib
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3
968
Graz, Innsbruck, Linz, Vienna
2019-03-01
Active, closed
Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa
NCT03827798Hidradenitis Suppurativa
DrugsMAS825·Ianalumab·Remibrutinib
Novartis Pharmaceuticals
Phase 2
248
Graz
2019-02-27
Active, closed
Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL
NCT03836261Chronic Lymphocytic Leukemia
DrugsVenclyxto·Venclexta·Acalabrutinib·Obinutuzumab
Acerta Pharma BV
Phase 3
984
Krems, Salzburg, Vienna
2019-02-25
Recruiting
ESAN II - Energy Sensing in Depression
NCT05432362Immune System Tolerance, Depression, Obesity, Microbial Colonization
Medical University of Graz
Not applicable
120
Graz
2019-02-25
Active, closed
Follow-up in Gynecological Cancer Survivors
NCT03515993Gynecologic Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Observational
1,100
Graz
2019-02-21
Active, closed
ABCSG C08-Exercise II: Trial of Endurance Exercise Following Adjuvant Chemotherapy for Colorectal Cancer
NCT03822572Colorectal Carcinoma
Austrian Breast & Colorectal Cancer Study Group
Not applicable
92
Salzburg, Graz, Kufstein, Braunau am Inn, Linz, Steyr, Wels
2019-02-14
Active, closed
Comparison of BioHPP (High Performance Polymer) - vs Titanium- vs Zirconia Abutments
NCT06737263Peri-implant Soft Tissue Healing
Medical University of Graz
Not applicable
60
Graz
2019-02-13
Recruiting
Rotation of Hydrophobic Acrylic Lenses - Rayner RA0800C & Alcon Clareon & Hoya Nanex & Hoya Vivinex XY1-EM & RayOne EMV Toric & PODEYE Toric
NCT03803852Age Related Cataracts, Astigmatism
Medical University of Vienna
Not applicable
750
Vienna
2019-01-21
Recruiting
Cold-induced Brown Fat Activation and Hepatic Steatosis
NCT03811236Non-Alcoholic Fatty Liver Disease
Medical University of Vienna
Not applicable
26
Vienna
2019-01-21
Recruiting
A Long-term Observational Study to Describe the Use of Vitamin-C Injektopas® 7.5 g in Patients With Vitamin C Deficiency
NCT06983847Deficiency, Vitamin C, Chronic Disease, Acute Disease
Pascoe Pharmazeutische Praeparate GmbH
Observational
1,000
Vienna, Etc.
2019-01-12
Active, closed
Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients
NCT03737643Advanced Ovarian Cancer
DrugsOlaparib·Durvalumab·Bevacizumab·Paclitaxel
AstraZeneca
Phase 3
1,407
Graz, Innsbruck, Linz, Vienna
2019-01-04
Active, closed
A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve
NCT03682536Myelodysplastic Syndromes
DrugsEpoetin Alfa·Eprex·Luspatercept
Celgene
Phase 3
363
Linz, Vienna
2019-01-02
Active, closed
The European Robotic Spinal Instrumentation (EUROSPIN) Study
NCT03398915Degenerative Disc Disease, Spondylolisthesis, Spinal Stenosis, Recurrent Disc Herniation
Marc Schröder
Observational
932
Innsbruck
2019-01-01
Active, closed
Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS
NCT03650114Relapsing Multiple Sclerosis
Drugs13-valent pneumococcal conjugate vaccine·23-valent pneumococcal polysaccharide vaccine·Ofatumumab
Novartis Pharmaceuticals
Phase 3
1,882
Vienna
2018-12-28
Active, closed
Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
NCT03734029Breast Cancer
DrugsEribulin·Trastuzumab deruxtecan·Nab-paclitaxel·Capecitabine
Daiichi Sankyo
Phase 3
557
Innsbruck, Linz, Salzburg, Vienna, Wels
2018-12-27
Active, closed
A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC
NCT03819465Metastatic Non-Small Cell Lung Cancer (NSCLC)
DrugsDanvatirsen·Oleclumab·Volrustomig·Rilvegostomig
AstraZeneca
Phase 1
175
Salzburg, Vienna
2018-12-27
Active, closed
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
NCT03711032High-risk Non-muscle Invasive Bladder Cancer
DrugsKeytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
1,397
Vienna, Innsbruck, Linz, Salzburg
2018-12-24
Recruiting
Study of Individuals Affected With Hypoplasminogenemia
NCT03797495Plasminogen Deficiency
Indiana Hemophilia &Thrombosis Center, Inc.
Observational
100
Innsbruck
2018-12-18
Active, closed
A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry Disease
NCT03737214Fabry Disease
Idorsia Pharmaceuticals Ltd.
Phase 3
107
Vienna
2018-12-18
Active, closed
Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)
NCT03765918Head and Neck Neoplasms
DrugsKeytruda·Cisplatin·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
714
Graz, Linz, Salzburg, Vienna
2018-12-17
Active, closed
A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer
NCT03701334Early Breast Cancer
DrugRibociclib
Novartis Pharmaceuticals
Phase 3
5,101
Innsbruck, Graz, Linz, Salzburg, Vienna
2018-12-07
Active, closed
A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer
NCT03800134Non-Small Cell Lung Cancer
DrugsDurvalumab·Pemetrexed·Gemcitabine·Paclitaxel
AstraZeneca
Phase 3
825
Graz, Innsbruck, Rankweil, Vienna
2018-12-06
Recruiting
Pulmonary Hemodynamics During Exercise - Research Network
NCT03954574Pulmonary Circulation Diseases
Medical University of Graz
Observational
1,500
Graz
2018-12-01
Recruiting
Retinal Photoreceptor Outer Segment Length Before and After Light Stimulation - a Pilot Study
NCT03921931Macular Degeneration, Dry, Primary Open-angle Glaucoma
Medical University of Vienna
Not applicable
35
Vienna
2018-11-26
Recruiting
Measurement of Total Retinal Blood Flow and Oxygen Extraction in Patients With Diabetes and Healthy Subjects
NCT03552562Retinal Blood Flow
Medical University of Vienna
Not applicable
120
Vienna
2018-11-21
Recruiting
Reproducibility of Dual Beam Doppler Fourier-domain Optical Coherence Tomography in Healthy Subjects
NCT03821467Ocular Blood Flow
Medical University of Vienna
Not applicable
20
Vienna
2018-11-19
Active, closed
Registry of Patients With Acute/Subacute Type B Aortic Dissection Treated by Means of the STABILISE Technique (STABILISE)
NCT03707743Aortic Dissection
IRCCS San Raffaele
Observational
200
Neulengbach
2018-10-30
Active, closed
A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
NCT03690388Differentiated Thyroid Cancer
DrugCabozantinib
Exelixis
Phase 3
187
Salzburg, Vienna
2018-10-05
Active, closed
A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia
NCT03589326Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
DrugsPonatinib·Imatinib·Vincristine·Methotrexate
Takeda
Phase 3
245
Vienna, Linz
2018-10-04
Active, closed
Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment.
NCT03647878Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
Ipsen
Observational
224
Leoben, Linz, Salzburg, Vöcklabruck, Wels
2018-09-24
Recruiting
Extension Study for the Port Delivery System With Ranibizumab (Portal)
NCT03683251Neovascular Age-Related Macular Degeneration
DrugPDS Implant with Ranibizumab
Hoffmann-La Roche
Phase 3
1,000
Graz, Vienna
2018-09-20
Active, closed
Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer
NCT03595592Invasive Breast Cancer
DrugsPerjeta·Herceptin·Tecentriq·Pertuzumab
Fondazione Michelangelo
Phase 3
650
Klagenfurt, Linz, Sankt Pölten, Vienna
2018-09-07
Active, closed
Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM
NCT03948035Newly Diagnosed Multiple Myeloma
DrugsElotuzumab·Carfilzomib·Lenalidomide·Dexamethasone
Wuerzburg University Hospital
Phase 3
576
Krems, Sankt Pölten, Graz, Innsbruck, Linz, Wels, Rankweil, Salzburg
2018-08-28
Active, closed
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis
NCT03398135Ulcerative Colitis (UC)
DrugsSkyrizi·Risankizumab
AbbVie
Phase 3
1,242
Sankt Pölten, Vienna, Graz, Linz, Salzburg
2018-08-28
Recruiting
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
NCT03486873Solid Tumors, Hematologic Malignancies
DrugsPembrolizumab/Favezelimab·) Berahyaluronidase alfa·Olaparib·Lenvatinib
Merck Sharp & Dohme LLC
Phase 3
3,500
Graz, Innsbruck, Linz, Salzburg, Vienna
2018-08-21
Active, closed
A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer
NCT03456076Carcinoma, Non-Small-Cell Lung
DrugsAlectinib·Vinorelbine·Pemetrexed·Gemcitabine
Hoffmann-La Roche
Phase 3
257
Vienna
2018-08-16
Active, closed
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
NCT03568318Atopic Dermatitis
DrugUpadacitinib
AbbVie
Phase 3
1,533
Vienna, Innsbruck, Linz
2018-08-09
Active, closed
Tailored Axillary Surgery With or Without Axillary Lymph Node Dissection Followed by Radiotherapy in Patients With Clinically Node-positive Breast Cancer (TAXIS)
NCT03513614Node-positive Breast Cancer
University Hospital, Basel, Switzerland
Not applicable
1,500
Dornbirn, Feldkirch, Innsbruck, Linz, Salzburg, Vienna, Wels
2018-08-07
Recruiting
Cochlear Implantation After Gamma Knife Radiosurgery with EABR and Correlation to Postoperative Hearing Results - a Pilot Study
NCT03745534Vestibular Schwannoma, Hearing Loss
Christoph Arnoldner
Observational
8
Vienna
2018-08-01
Recruiting
Secondary Sclerosis Cholangitis Prospective
NCT03566797Secondary Sclerosis Cholangitis in Critically Ill Patients
Medical University of Graz
Observational
380
Graz
2018-07-20
Recruiting
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
NCT03435796Neoplasms
Celgene
Phase 2/3
1,541
Linz, Vienna
2018-07-19
Active, closed
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)
NCT03519945Ulcerative Colitis
DrugMirikizumab
Eli Lilly and Company
Phase 3
1,058
Innsbruck, Salzburg, Vienna
2018-07-18
Recruiting
Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017
NCT03643276Acute Lymphoblastic Leukemia, Pediatric
DrugsBlinatumomab·Daunorubicin·Bortezomib·Cytarabine
Martin Schrappe
Phase 3
5,000
Graz, Innsbruck, Linz, Salzburg, Vienna
2018-07-15
Active, closed
AGRA Before and After Liver Transplantation
NCT03446521Liver Cirrhosis
Medical University of Graz
Observational
76
Graz
2018-07-06
Recruiting
A Multicenter Patient Registry on Outcomes From Cryoanalgesia of the Intercostal Nerves
NCT05110989Post Operative Pain
AtriCure, Inc.
Observational
5,000
Vienna
2018-06-29
Recruiting
Mucous Fistula Refeeding Reduces the Time From Enterostomy Closure to Full Enteral Feeds ("MUC-FIRE" Trial)
NCT03469609Enterostomy
University of Leipzig
Not applicable
120
Graz, Vienna
2018-06-18
Active, closed
Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy
NCT03755791Hepatocellular Carcinoma
DrugsSorafenib·Cabozantinib·Atezolizumab
Exelixis
Phase 3
837
Klagenfurt, Sankt Pölten, Graz, Linz, Vienna
2018-06-10
Active, closed
Histological/ Immunohistological and Molecularpathological Types of Epulides and Central Giant Cell Lesions of the Jaws
NCT03829059Epulis
Medical University of Graz
Observational
83
Graz
2018-06-01
Active, closed
Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer
NCT03528694Non-muscle-invasive Bladder Cancer
DrugsBacillus Calmette-Guerin·Durvalumab
AstraZeneca
Phase 3
1,018
Graz, Innsbruck, Linz, Salzburg, Vienna
2018-05-14
Active, closed
Observation of Clinical Routine Care for Heart Failure Patients Implanted With BIOTRONIK CRT Devices
NCT03366545Heart Failure
Biotronik SE & Co. KG
Observational
3,030
Linz, Sankt Pölten, Vienna
2018-05-14
Active, closed
Extended Access of Momelotinib in Adults With Myelofibrosis
NCT03441113Neoplasms, Post-polycythemia Vera Myelofibrosis (Post-PV MF), Primary Myelofibrosis (PMF), Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
GlaxoSmithKline
Phase 2
237
Linz, Vienna
2018-05-03
Rows per page Showing 1301–1400 of 1573
Previous 12 13 14 15 16 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Austrian investigative site. Derived from ClinicalTrials.gov. Retrieved 28 September 2026. https://priyalifescience.com/clinical-trials-austria?page=14

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Austria and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 1,573 studies in total at the last sync on 26 Sep 2026, 19:45 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

How many clinical trials are recruiting in Austria?

850 of the 1,573 studies in this register are recruiting new participants as of the 26 Sep 2026, 19:45 UTC sync. A further 89 have not yet opened recruitment, 590 are active but closed to new participants, and 44 are enrolling by invitation only. Eligibility for any study is decided by its study team.

This register, in your inbox every Friday

One email a week with how many trials are recruiting in Ireland, new EMA and FDA approvals and medicine shortages, built from the same public registers as this page.

Free. Unsubscribe from any email with one click. See our privacy policy.

→

Browse trials by condition

Breast Cancer (24) Multiple Myeloma (18) Ulcerative Colitis (18) Heart Failure (16) Crohn's Disease (15) Coronary Artery Disease (14) Atrial Fibrillation (14) Chronic Lymphocytic Leukemia (13) Non-small Cell Lung Cancer (12) Obesity (11) Non-Small Cell Lung Cancer (11) Cataract (11) Acute Myeloid Leukemia (10) Carcinoma, Non-Small-Cell Lung (10) Pulmonary Hypertension (9)
→

Browse trials by site location

Vienna (1005) Graz (506) Linz (438) Innsbruck (398) Salzburg (291) Sankt Pölten (113) Wels (92) Klagenfurt (62) Feldkirch (49) Krems (34) Wiener Neustadt (33) Leoben (27) Rankweil (24) Braunau am Inn (17) Steyr (14)
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.